If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number of FDA-approved biosimilars to 63. Forty-one of those biosimilars have ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

The Food and Drug Administration has approved Celltrion’s Omlyclo (omalizumab-igec) as a biosimilar designated as interchangeable with Xolair (omalizumab) for the treatment of moderate to severe ...

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.

Elevidys contains the active ingredient delandistrogene moxeparvovec-rokl, and it’s available only as a brand-name biologic drug. It doesn’t come in a biosimilar version. A biosimilar ...

That changed when CVS Health removed Humira from its list of covered drugs and more patients switched to a biosimilar in three weeks than had in the prior 15 months. CVS, which owns a pharmacy ...

SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Program, including ...